With rigorous economic research and practical policy solutions, we focus on the issues and institutions that are critical to global development. Explore our core themes and topics to learn more about our work.
In timely and incisive analysis, our experts parse the latest development news and devise practical solutions to new and emerging challenges. Our events convene the top thinkers and doers in global development.
As more countries rise out of poverty, CGD’s work in this area focuses on the inequities and emerging problems that jeopardize global health progress.
As more countries rise out of poverty, CGD is focusing on the inequities and emerging problems that jeopardize global health progress: How should governments allocate scarce health budgets rationally and equitably? How can the world advance global health security and fight infectious diseases? What can be done to address treatment inequalities between developed and developing countries? What are the benefits of, mechanisms for, and threats to, greater family planning provision? CGD research helps policymakers build sustainable health systems, respond to shifting realities, and deliver value for money.
Philip Morris International and other cigarette manufacturers are among the most profitable firms in the world, selling the world’s most lethal legal product. They prominently advertise their commitment to corporate social responsibility on everything from child labor to renewable energy. They’ve even conceded that smoking is dangerous and say they are committed to a smoke-free world. But none of these initiatives make up for breaching their most fundamental corporate social responsibility—one defined quite cogently by free-market-advocate Milton Friedman—to pursue their profits “without deception and fraud.”
Health products—including drugs, devices, diagnostics, and vector control tools—are essential for meeting the healthcare needs of any population. Right now, many low- and lower-middle-income countries rely on donor-managed mechanisms to procure a large share of these health commodities. But this status quo won’t stay static for long, and the global health community must prepare for sweeping changes in global health and procurement over the next 10–20 years. Here’s some of what we see happening now and on the immediate horizon.
The 2014-2015 Ebola epidemic broke out and affected thousands of people at a time when there were no medicines approved to treat or prevent Ebola. Poor infrastructure, capacity gaps, widespread mistrust, and disagreements over the design and ethical nature of any clinical trials complicated efforts to conduct research on investigational drugs and vaccines. In the wake of the outbreak, the National Academies of Sciences, Engineering, and Medicine tasked a committee with analyzing the clinical trials carried out during the outbreak and developing recommendations to improve the implementation of such trials in the future. In this session, committee members Gerald Keusch and David Peters will discuss findings from the committee’s recently released report and the kind of governance structures that need to be in place for effective international coordination and collaboration.
As part of its national health reforms, El Salvador assigned community health teams to 98 of its poorest municipalities. While some municipalities received traditional (input-based) aid to support the program and others received national funding, some municipalities received funding through the Salud Mesoamerica Initiative (SMI), a results-based aid (RBA) program focused on maternal and child health targets. In this seminar, Sebastian Martinez will present on his new research with Pedro Bernal and Pablo Celhay, which uses a difference-in-difference design to assess whether municipalities that received RBA funding were more effective at delivering health services. Martinez will also discuss the program's spillover effects on men and the elderly, as well as its implications for population health.